One limitation of the overall strategy of targeting hepatic UGT1A1 to increase plasma bilirubin levels for the treatment of NAFLD is the wide range of substrates of UGT1A1, which was also indicated by the kinome analysis. This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.